Skip to main content

Table 1 Human synaptic plasticity genes expression in HIV infected neuronal cells and in combination with nicotine and/or vorinostat (fold change)

From: Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder

Genes Vorinostat HIV HIV + Vorinostat Nicotine Nicotine + Vorinostat HIV + Nocotine HIV + Nicotine + Vorinostat
ADAM10 5,6,9 1.47 1.89 1.24 4.12 1.45 -1.03 1.11
ADCY1 3 1.12 -3.39 1.12 -3.15 2.26 -3.99 1.17
ADCY8 3 1.12 -3.39 1.12 -3.15 2.26 -3.99 -1.96
AKT1 7 3.10 2.96 3.84 3.42 4.59 -1.32 4.23
ARC 1,9 -1.09 1.30 1.54 1.07 2.79 -4.81 1.55
BDNF 1,3 1.12 -3.39 1.12 -3.15 2.26 -3.99 -1.96
CAMK2A 3 1.12 -3.39 1.12 -3.15 2.26 -3.99 -1.96
CAMK2G 3,7 1.48 1.11 1.46 1.16 1.62 -3.38 1.33
CDH2 3,5 1.12 -3.06 1.12 -3.15 2.26 -3.99 -1.37
CEBPB 1 1.37 2.50 1.64 1.98 2.07 -3.07 2.04
CEBPD 1 1.39 1.89 1.96 1.35 3.03 -3.07 1.96
CNR1 3 1.12 -3.39 1.12 -3.15 2.26 -3.99 -1.96
CREM 1 -35.90 -9.78 -15.78 -8.26 -16.02 -25.41 -16.77
EGR1 1 2.37 1.13 1.34 -5.68 1.15 -9.24 1.20
EGR2 1 6.89 1.94 4.29 9.22 3.34 1.43 2.43
EGR3 1 1.86 1.01 3.89 -1.76 2.94 -3.99 2.43
EGR4 1 -1.95 -6.69 -1.96 -3.20 1.03 -8.74 -4.28
EPHB2 8 1.71 -2.97 1.74 -3.15 2.36 -3.99 1.43
FOS 1 1.15 -1.24 1.07 1.07 1.43 -3.83 -1.12
GABRA5 3,8 1.91 -3.39 1.12 -1.62 2.26 -3.99 -1.96
GRIA1 3,4,8,9 1.12 -3.39 1.12 -3.15 2.26 -3.99 -1.96
GRIA2 3,4,8 4.04 2.38 2.55 2.09 4.40 1.10 3.49
GRIA4 4,8,9 12.85 9.24 4.35 2.39 5.73 -1.50 3.12
GRIN1 3,7,8,9 31.65 5.89 28.25 4.70 39.89 -1.02 35.80
GRIN2A 3,5,7,8,9 2.26 -3.06 1.12 -2.14 2.26 -3.99 -1.07
GRIN2B 3,5,7,8,9 2.26 -3.39 1.12 -3.15 2.26 -3.99 -1.07
GRIN2C 3,7,8,9 2.26 -1.73 1.80 -3.15 2.26 -3.99 -1.07
GRIN2D 3,7,8 4.25 1.42 2.17 4.97 4.25 -1.34 2.80
GRIP1 4 3.07 -1.09 2.36 2.72 3.07 -1.90 1.96
GRM1 4,8,9 1.12 -3.39 1.12 -3.15 2.26 -3.99 -1.96
GRM2 4,8 1.85 1.93 1.12 3.79 2.26 -1.47 1.01
GRM3 8,9 1.12 -3.39 1.12 -2.11 2.26 -3.99 -1.96
GRM4 8 2.26 -3.06 1.12 1.34 2.26 -3.99 -1.21
GRM5 8 1.12 3.38 1.12 -1.15 2.26 -2.75 -1.96
GRM7 8 1.12 -3.06 1.12 2.45 2.26 -2.33 -1.10
HOMER1 1,9 -1.64 -1.13 -2.95 1.30 -2.68 -1.93 -3.13
IGF1 4 1.96 9.13 1.32 11.75 1.19 3.37 1.17
INHBA 2 4.15 -2.11 2.03 -1.43 2.22 -5.89 2.25
JUN 1 8.84 -1.39 6.73 -1.65 8.04 -11.61 6.33
JUNB 1 3.93 2.73 4.06 1.42 10.84 -3.97 3.79
KIF17 10 2.30 -2.99 3.20 -1.89 4.19 -9.30 3.34
MMP9 1,3,6 3.06 -2.68 2.00 -2.94 2.99 -10.32 1.62
NCAM1 5 1.17 -4.59 1.41 -6.80 1.40 -39.88 1.25
NFKB1 1 -20.48 -6.41 -35.26 -5.45 -26.76 -25.59 -48.77
NFKBIB 1 9.61 12.91 13.09 14.56 14.20 13.54 13.66
NGF 1,4 5.79 1.45 4.92 1.30 4.72 -3.01 6.55
NGFR 4 1.30 2.50 1.13 2.65 1.37 -2.18 1.04
NOS1 4 1.12 -3.39 1.12 1.22 2.26 -3.99 -1.96
NPTX2 1 1.12 2.22 1.12 1.28 2.26 -3.29 3.19
NR4A1 1 5.11 1.47 6.73 2.54 4.82 -1.79 4.67
NTF3 1 1.12 -3.06 1.12 1.92 2.26 -1.53 -1.96
NTF4 3 1.98 1.14 4.82 -1.30 5.85 -6.14 4.63
NTRK2 3 1.12 -3.40 1.12 -3.15 2.26 -3.99 -1.96
PCDH8 1,5 2.37 2.53 1.29 3.37 2.04 -1.68 1.35
PICK1 4,9 1.58 1.54 2.64 1.18 2.65 -4.21 2.30
PIM1 1 11.19 4.86 25.46 10.59 33.08 2.55 32.95
PLAT 1,4,6 -1.03 -1.82 -1.03 -2.34 1.97 -4.59 -2.25
PLCG1 3 2.19 1.23 2.35 1.39 3.78 -3.62 2.91
PPP1CA 3,4,7 -2.04 1.54 1.37 -1.69 1.16 -13.25 1.48
PPP1R14A 4 1.12 -3.06 1.12 -3.15 2.26 -3.99 -1.96
PPP2CA 4 6.52 10.06 6.87 13.31 7.20 3.28 6.64
PRKCA 3,4 5.40 2.80 3.29 7.23 4.43 2.24 2.93
PRKCG 3 2.30 -5.07 2.16 -4.84 3.22 -6.62 2.12
PRKG1 4 1.12 -3.06 1.12 -3.15 2.26 -3.99 -1.47
RAB3A 3 86.46 56.49 106.15 75.27 91.65 15.81 103.39
RELA 1 1.30 2.00 1.34 3.26 1.45 -1.12 1.25
RELN 5,6 1.12 -3.06 1.12 -3.15 2.26 -3.99 -1.96
RGS2 1 5.29 -1.40 2.62 -1.12 4.46 -2.90 2.38
RHEB 1 -49.73 -32.90 -57.68 -35.16 -46.92 -84.30 -69.94
SIRT1 10 2.29 2.58 1.91 4.70 1.89 1.52 1.28
SRF 1 2.70 2.83 1.82 3.19 2.33 -1.44 1.60
TIMP1 6 -18.20 -38.00 -20.11 -24.02 -15.69 -79.20 -17.73
TNF 1,5 -2.65 -5.47 -2.28 -2.63 -1.42 -5.97 -9.30
  1. Out of 84 genes analyzed, only genes significantly (± ≥ 3 fold) dysregulated were shown in this table.
  2. 1Immediate Early Response Genes; 2Late Response Genes; 3Long Term Potentiation; 4Long Term Depression; 5Cell Adhesion; 6Extracellular Matrix & Proteolytic Processing; 7CREB Cofactors; 8Neuronal Receptors; 9Postsynaptic Density; 10Others.
  3. If the synaptic plasticity genes expression change is ± ≥3 fold, the fold change was represented in bold letters.